Efficacy and safety of a novel pegylated interferon alpha-2a in Egyptian patients with genotype 4 chronic hepatitis C.
作者： Alaa Awad Taha , Ahmad El-Ray , Maged El-Ghannam , Bahaa Mounir
DOI: 10.1155/2010/717845
关键词: Pegylated interferon 、 Virology 、 Immunology 、 Hepatitis C 、 Viral load 、 Liver disease 、 Ribavirin 、 Alpha interferon 、 Medicine 、 Hepacivirus 、 Hepatitis C virus
摘要: BACKGROUND: Hepatitis C virus (HCV) genotype 4 is a common infection in Egypt and the leading cause of liver disease.
hindawi.com
cabdirect.org
core.ac.uk 参考文章(28)
O Selim, P Simmonds, S Haddad, A el-Zayadi, H M Badran, H Hamdy, S Shawky, Combination treatment of interferon alpha-2b and ribavirin in comparison to interferon monotherapy in treatment of chronic hepatitis C genotype 4 patients. Italian Journal of Gastroenterology and Hepatology. ,vol. 31, pp. 472- 475 ,(1999)
Alessandra Mangia, Rosanna Santoro, Nicola Minerva, Giovanni L. Ricci, Vito Carretta, Marcello Persico, Francesco Vinelli, Gaetano Scotto, Donato Bacca, Mauro Annese, Mario Romano, Franco Zechini, Fernando Sogari, Fulvio Spirito, Angelo Andriulli, Peginterferon alfa-2b and ribavirin for 12 vs. 24 weeks in HCV genotype 2 or 3. The New England Journal of Medicine. ,vol. 352, pp. 2609- 2617 ,(2005) , 10.1056/NEJMOA042608
Sanaa M. Kamal, Samer S. El Kamary, Michelle D. Shardell, Mohamed Hashem, Imad N. Ahmed, Mohamed Muhammadi, Khalifa Sayed, Ashraf Moustafa, Sarah Abdel Hakem, Amany Ibrahiem, Mohamed Moniem, Hoda Mansour, Mohamed Abdelaziz, Pegylated interferon alpha‐2b plus ribavirin in patients with genotype 4 chronic hepatitis C: The role of rapid and early virologic response Hepatology. ,vol. 46, pp. 1732- 1740 ,(2007) , 10.1002/HEP.21917
Vincent G Bain, Kelly D Kaita, Paul Marotta, Eric M Yoshida, Mark G Swain, Robert J Bailey, Keyur Patel, Patrick W Cronin, Erik Pulkstenis, John G McHutchison, G Mani Subramanian, None, Safety and Antiviral Activity of Albinterferon Alfa-2b Dosed Every Four Weeks in Genotype 2/3 Chronic Hepatitis C Patients Clinical Gastroenterology and Hepatology. ,vol. 6, pp. 701- 706 ,(2008) , 10.1016/J.CGH.2008.02.056
YOSHIYASU KARINO, JOUJI TOYOTA, MASAAKI SUGAWARA, KAYO MIYAZAKI, YASUAKI KUWATA, KATSU YAMAZAKI, TAKAHIRO SATO, TAKUMI OHMURA, TAKASHI MATSUSHIMA, Hepatitis C virus genotypes and hepatic fibrosis regulate 24-h decline of serum hepatitis C virus RNA during interferon therapy in patients with chronic hepatitis C. Journal of Gastroenterology and Hepatology. ,vol. 18, pp. 404- 410 ,(2003) , 10.1046/J.1440-1746.2003.03009.X
Peter Ferenci, Michael W. Fried, Mitchell L. Shiffman, Coleman I. Smith, George Marinos, Fernando L. Gonçales, Dieter Häussinger, Moises Diago, Giampero Carosi, Daniel Dhumeaux, Antonio Craxì, Monique Chaneac, K. Rajender Reddy, Predicting sustained virological responses in chronic hepatitis C patients treated with peginterferon alfa-2a (40KD)/ribavirin Journal of Hepatology. ,vol. 43, pp. 425- 433 ,(2005) , 10.1016/J.JHEP.2005.04.009
Stefan Zeuzem, Eric M Yoshida, Yves Benhamou, Stephen Pianko, Vincent G Bain, Daniel Shouval, Robert Flisiak, Vratislav Rehak, Mircea Grigorescu, Kelly Kaita, Patrick W Cronin, Erik Pulkstenis, G Mani Subramanian, John G McHutchison, None, Albinterferon alfa‐2b dosed every two or four weeks in interferon‐naïve patients with genotype 1 chronic hepatitis C Hepatology. ,vol. 48, pp. 407- 417 ,(2008) , 10.1002/HEP.22403
G L Davis, J Y Lau, Factors predictive of a beneficial response to therapy of hepatitis C Hepatology. ,vol. 26, ,(1997) , 10.1002/HEP.510260721
Michael W. Fried, Mitchell L. Shiffman, K. Rajender Reddy, Coleman Smith, George Marinos, Fernando L. Gonçales, Dieter Häussinger, Moises Diago, Giampiero Carosi, Daniel Dhumeaux, Antonio Craxi, Amy Lin, Joseph Hoffman, Jian Yu, Peginterferon alfa-2a plus ribavirin for chronic hepatitis C virus infection. The New England Journal of Medicine. ,vol. 347, pp. 975- 982 ,(2002) , 10.1056/NEJMOA020047
G. Esmat, S. Abdel Fattah, Evaluation of a novel pegylated interferon alpha-2a (Reiferon Retard®) in Egyptian patients with chronic hepatitis C – genotype 4 Digestive and Liver Disease Supplements. ,vol. 3, pp. 17- 19 ,(2009) , 10.1016/S1594-5804(09)60011-5